advertisement
Abstract #92476 Published in IGR 22-1
Stanniocalcin-1 Reduced Intraocular Pressure in Two Models of Ocular Hypertension
Roddy GW; Chowdhury UR; Monson KJ; Fautsch MPCurrent Eye Research 2021; 0: 1-6
: Glaucomatous optic neuropathy (GON) remains the world's leading cause of irreversible blindness. Treatments including topical medications are directed at reducing intraocular pressure (IOP), the most significant risk factor for GON. Current medications, while generally effective, are limited by insufficient response and side-effects in some patients. In search of a more targeted therapy that acts downstream of existing medications that has a potential for a lower side effect profile, our laboratory has identified Stanniocalcin-1 (STC-1), a multifunctional hormone, as an effector molecule in latanoprost-mediated IOP reduction with similar IOP-lowering efficacy as latanoprost in normotensive mice.: To investigate whether STC-1 can also reduce IOP in ocular hypertensive mice, we used a steroid-induced ocular hypertensive mouse model characterized by trabecular meshwork dysfunction as well as the DBA/2J mouse as an inherited model of pigment dispersion and secondary angle closure. Steroid-induced ocular hypertension was induced by weekly injections of dexamethasone into the conjunctival fornix of wild-type C57BL/6J mice (6-8 months old). After confirmation of the steroid response, mice were administered STC-1 or phosphate buffered saline (PBS) topically once daily for six weeks. For DBA/2J mice (14 months old), after baseline IOP measurements, mice were treated topically once daily with STC-1 or PBS for 5 days and IOP was assessed twice daily.: In steroid-induced ocular hypertensive mice, STC-1 lowered IOP by 26% ( < .001, week three) and maintained this level of IOP reduction throughout the remainder of the treatment period ( < .001, week six). In DBA/2J mice, STC-1 lowered IOP by 37% ( < .001).: Together, these data show that STC-1 reduced IOP in two models of ocular hypertension with different mechanisms of outflow obstruction.
Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA.
Full articleClassification:
5.1 Rodent (Part of: 5 Experimental glaucoma; animal models)
9.4.1 Steroid-induced glaucoma (Part of: 9 Clinical forms of glaucomas > 9.4 Glaucomas associated with other ocular and systemic disorders)
11.14 Investigational drugs; pharmacological experiments (Part of: 11 Medical treatment)
